SynthesisEuropean journal of neurology2020
Guillain-Barré syndrome associated with SARS-CoV-2 infection. A systematic review.
Synthesis in European journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Miller Fisher syndrome associated with COVID-19: an up-to-date systematic review.Environmental science and pollution research international · 2021Pooled it
- The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - A systematic review of the literature.Journal of autoimmunity · 2021Pooled it
- Guillain-Barré syndrome (GBS) after severe/critical COVID-19 or COVID-19 vaccination.European journal of medical research · 2025Article
- Evaluation and Comparison of Treatment Response and In-Hospital Prognosis of COVID-19-Related Guillain-Barre Syndrome with Non-COVID-19 Patients.Medical journal of the Islamic Republic of Iran · 2025Article
- Complex Interplay of COVID-19 ARDS with Guillain-Barré Syndrome and Cerebral Infarction: A Case Study.The American journal of case reports · 2024Article
- Letter to the Editor: SARS-CoV-2-Related Polyradiculitis Requires Exclusion of Alternative Causes and Long-Term Follow-up.Journal of Korean medical science · 2024Article
- Guillain-Barré Syndrome After COVID-19 Infection in Korea: A Case Series.Journal of Korean medical science · 2024Article
- Retrospective analysis of COVID-19 patients with Guillain-Barre, Miller-Fisher, and opsoclonus-myoclonus-ataxia syndromes-a case series.Wiener medizinische Wochenschrift (1946) · 2024Article
- Neurologic and Neuromuscular Sequelae of COVID-19.Physical medicine and rehabilitation clinics of North America · 2023Review
- Immediate and contributory causes of death in patients hospitalized with COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- [COVID-19: Neurological manifestations and complications during the acute phase of the disease].Bulletin de l'Academie nationale de medecine · 2023Review
- Guillain-Barré syndrome AMSAN variant in a 90-year-old woman after COVID-19: a case report.BMC geriatrics · 2023Article
- Is there a causal nexus between COVID-19 infection, COVID-19 vaccination, and Guillain-Barré syndrome?European journal of medical research · 2023Review
- The Profile of Guillain-Barré Syndrome Before and During COVID-19 Pandemic: A 5-Year Experience.Noro psikiyatri arsivi · 2023Article
- Neuro-COVID-19.Clinical & experimental neuroimmunology · 2022Review
- Guillain-Barré syndrome following different COVID-19 vaccines: a case series.The Egyptian journal of neurology, psychiatry and neurosurgery · 2022Article
- Is there a difference between GBS triggered by COVID-19 and those of other origins?The Egyptian journal of neurology, psychiatry and neurosurgery · 2022Article
- Neurologic complications of coronavirus and other respiratory viral infections.Handbook of clinical neurology · 2022Review
- [Neurological complications and consequences of new coronavirus COVID-19 infection in elderly and old patients (literature review).]Advances in gerontology = Uspekhi gerontologii · 2022Article
- Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study.Brain : a journal of neurology · 2021Observational
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré syndrome (GBS) incidence can increase during outbreaks of infectious illnesses. A few cases of GBS associated with coronavirus disease 2019 (COVID-19) infection have been reported. The aim was to identify specific clinical features of GBS associated with COVID-19. PubMed, Embase and Cochrane were searched from 1 November 2019 to 17 May 2020 and included all papers with full text in English, Spanish, French or Italian, reporting original data of patients with GBS and COVID-19. Data were extracted according to a predefined protocol. A total of 18 patients reported in 14 papers were included in this review. All the patients were symptomatic for COVID-19, with cough and fever as the most frequently reported symptoms. The interval between the onset of symptoms of COVID-19 and the first symptoms of GBS ranged from -8 to 24 days (mean 9 days; median 10 days). Most of the patients had a typical GBS clinical form predominantly with a demyelinating electrophysiological subtype. Mechanical ventilation was necessary in eight (44%) patients. Two (11%) patients died. Published cases of GBS associated with COVID-19 report a sensorimotor, predominantly demyelinating GBS with a typical clinical presentation. Clinical features and disease course seem similar to those observed in GBS related to other etiologies. These results should be interpreted with caution since only 18 cases have been heterogeneously reported so far.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.